Pfizer
NEWS
If authorized, it could be available in the U.S. before the end of the year. It is also working to submit applications to other regulators worldwide.
Two companies reported regulatory submissions to the FDA, and a third reported successful clinical trial data that will form the basis of submission in the coming months.
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
The question is continually being raised: what offers superior protection, a vaccine against COVID-19 or natural immunity?
Moderna seeks to invalidate two patents of Arbutus Biopharma Corp. The company hopes to appeal a preemptive challenge to the patents upheld by the U.S. Patent Trial and Appeals Board.
JOBS
IN THE PRESS